1. BRACAnalysis CDx™ is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza™ (olaparib). This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108.
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.
Medicare Informed Consent Form – A copy of this document is required for Medicare patients who meet Medicare criteria or as a substitute for the Informed Consent documentation requirement on the test request form. En Español
Medicaid Waver - Patients with Medicaid who do not have coverage for testing but would like to proceed with testing must complete this form.
Myriad Financial Assistance Program - If a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction, GUARANTEED.
Non-covered Services Consent Form - Patients who do not have coverage for testing through their insurance but would like to proceed with testing must complete this form when their insurance requires written documentation from the patient that they would like to proceed with testing despite no coverage through their insurance.
Pedigree Template — this form can be used to assist healthcare providers in completing a 3 generational pedigree.
Return Sample Request Form – This document allows Myriad to send remaining DNA to another facility or DNA banking facility. Please note that in addition to this form, a $50.00 fee is required.
Sample Destruction Request Form – This document is for patients who do not want Myriad to retain their DNA for the usual 60 day time period after test release or cancellation.
Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.